Cargando…
Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains most...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478540/ https://www.ncbi.nlm.nih.gov/pubmed/36119518 http://dx.doi.org/10.3389/fonc.2022.953908 |
_version_ | 1784790596183916544 |
---|---|
author | Kachmazov, Andrei Bolotina, Larisa Kornietskaya, Anna Kuznetsova, Olesya Ivanov, Maxim Fedenko, Alexander |
author_facet | Kachmazov, Andrei Bolotina, Larisa Kornietskaya, Anna Kuznetsova, Olesya Ivanov, Maxim Fedenko, Alexander |
author_sort | Kachmazov, Andrei |
collection | PubMed |
description | PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains mostly undetermined. Here we report a clinical case of a 56-year-old woman with pancreatic ductal adenocarcinoma harboring a somatic PALB2 mutation. Following disease progression after 10 cycles of FOLFIRINOX chemotherapy and two cycles of second-line gemcitabine, she was switched to talazoparib and achieved a complete clinical response after 25 months of treatment. The patient remains alive without clinical or radiological signs of disease progression three years after the start of talazoparib with no targeted therapy-related toxicities. This case highlights the role of broad molecular profiling as a window of opportunity to achieve a durable response for selected pancreatic cancer patients while pinpointing our gaps in understanding the whole picture of management of these patients since a new puzzle element represented by PARP inhibitors was introduced to clinical practice. |
format | Online Article Text |
id | pubmed-9478540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94785402022-09-17 Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review Kachmazov, Andrei Bolotina, Larisa Kornietskaya, Anna Kuznetsova, Olesya Ivanov, Maxim Fedenko, Alexander Front Oncol Oncology PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains mostly undetermined. Here we report a clinical case of a 56-year-old woman with pancreatic ductal adenocarcinoma harboring a somatic PALB2 mutation. Following disease progression after 10 cycles of FOLFIRINOX chemotherapy and two cycles of second-line gemcitabine, she was switched to talazoparib and achieved a complete clinical response after 25 months of treatment. The patient remains alive without clinical or radiological signs of disease progression three years after the start of talazoparib with no targeted therapy-related toxicities. This case highlights the role of broad molecular profiling as a window of opportunity to achieve a durable response for selected pancreatic cancer patients while pinpointing our gaps in understanding the whole picture of management of these patients since a new puzzle element represented by PARP inhibitors was introduced to clinical practice. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9478540/ /pubmed/36119518 http://dx.doi.org/10.3389/fonc.2022.953908 Text en Copyright © 2022 Kachmazov, Bolotina, Kornietskaya, Kuznetsova, Ivanov and Fedenko https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kachmazov, Andrei Bolotina, Larisa Kornietskaya, Anna Kuznetsova, Olesya Ivanov, Maxim Fedenko, Alexander Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review |
title | Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review |
title_full | Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review |
title_fullStr | Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review |
title_full_unstemmed | Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review |
title_short | Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review |
title_sort | complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic palb2 mutation: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478540/ https://www.ncbi.nlm.nih.gov/pubmed/36119518 http://dx.doi.org/10.3389/fonc.2022.953908 |
work_keys_str_mv | AT kachmazovandrei completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview AT bolotinalarisa completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview AT kornietskayaanna completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview AT kuznetsovaolesya completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview AT ivanovmaxim completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview AT fedenkoalexander completeresponsetotalazoparibinpatientwithpancreaticadenocarcinomaharboringsomaticpalb2mutationacasereportandliteraturereview |